Article

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy

2021-06-04

Abstract excerpt

As of October 2021, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta var...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2c1e938-9971-506c-997f-e7c50c7b3fc5
DOI: 10.1101/2021.06.04.447066

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapyDOI 10.1101/2021.06.04.447066Read

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol deliverySemantic proximity Read

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibodySemantic proximity Read

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoVSemantic proximity Read

Intranasal delivery of a broadly neutralizing single domain antibody targeting ACE2 protects against SARS-CoV-2 infectionSemantic proximity Read

AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In VivoSemantic proximity Read

Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibodySemantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity Read

Neutralization Of SARS-CoV-2 Variants By A Human Polyclonal Antibody Therapeutic (COVID-HIG, NP-028) With High Neutralizing Titers To SARS-CoV-2Semantic proximity Read

Inhalable nanocatchers for SARS-CoV-2 inhibitionSemantic proximity Read

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variantsSemantic proximity Read

The real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19Semantic proximity Read

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodentsSemantic proximity Read